Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Naloxone Nasal Spray vs IM Injection in Healthy Volunteers
NCT03827629Phase 1Completed
- Sponsor
- Insys Therapeutics
- Start
- Aug 2017
- Primary completion
- Aug 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of naloxone in opioid overdose (6 arms), sponsored by Insys Therapeutics. Primary endpoints: Plasma Concentration of Unconjugated Naloxone and Partial Area Under the Concentration Curve of Unconjugated Naloxone. Started Aug 2017; status: completed.
02
Drugs
naloxone
03
Conditions
opioid overdose
Beyond the preview
Go deeper on NCT03827629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03827629.